Alnylam Pharmaceuticals, Inc.(ALNY), an RNAi therapeutics company, on Thursday reported a net income for the first quarter of fiscal 2026, supported by a surge in revenue, driven by net product revenues.
Yvonne Greenstreet, CEO of Alnylam, said: "2026 is off to a strong start for Alnylam with the end of the first quarter marking one year since the U.S. launch of AMVUTTRA for ATTR-CM, and also representing a significant financial milestone with the achievement of over $1 billion in quarterly product revenues for the first time in our history."
For the three-month period to March 31, the drugmaker reported a net income of $205.991 million, compared with a net loss of $18.251 million in the same period last year. Net profit per share stood at $1.51 as against a net loss of $0.14 per share a year ago. Excluding items, earnings were $273.038 million, or $1.99 per share, compared with $37.941 billion, or $0.29 per share, last year.
Income from operations surged to $268.636 million from $18.077 million in the previous year.
Total revenue was $1.167 billion, up from $594.189 million in the previous year. Net product revenues jumped to $1.036 billion from $468.538 million last year. Revenue from AMVUTTRA was $889.931 million, higher than $309.992 million a year ago.
Looking ahead for fiscal 2026, Alnylam has reaffirmed total net product revenue guidance of $4.900 billion to $5.300 billion, up 64% to 77% from last year.
ALNY was up by 8.57% at $327 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.